FOLD : Analysis & Opinions

  1. Gilead Sciences Leads In Rising Short Interest Among Biotechs

    November 12, 2013
    Among leading biotech and emerging pharmaceutical companies, the number of shares sold short in Alexion Pharmaceuticals ...
  2. A Triple Play Of Biotech Disappointments Last Week

    December 28, 2012
    Investors got a triple-dose of bad biotech news this week.
  3. Glaxo/Amicus' Fabry Drug Disappoints - Analyst Blog

    December 21, 2012
    GlaxoSmithKline (GSK) and partner Amicus Therapeutics (FOLD) recently presented disappointing top-line six-month primary ...
  4. Glaxo Increases Stake in RGDX - Analyst Blog

    September 18, 2012
    GlaxoSmithKline (GSK) recently announced it has hiked its stake in Response Genetics Inc. (RGDX), a company focused on the ...
  5. Glaxo to Increase Stake in Amicus - Analyst Blog

    July 19, 2012
    Glaxo Group Limited, an affiliate of GlaxoSmithKline (GSK), and Amicus Therapeutics (FOLD) recently announced the expansion ...
Investing News
  1. Infographic - The Lifecycle of a Bond

    Basic information on how Bonds work.
  2. What $200,000 Will Buy In The Atlanta Real Estate Market

    Atlanta housing prices are up from last year, but they're still lower than the national median. ...
  3. Bubble Bursting? Only For Biotech & Internet Stocks

    The recent sluggish performance of U.S. stocks is leading some market watchers to question ...
  4. What $300,000 Will Buy In The Riverside/San Bernardino Real Estate Market

    The median list price for the San Bernardino/Riverside, Calif. market is $292,800, up 24.6% ...
  5. What Is Worse Than Being At Risk?

    You may have heard the old adage: “What is worse than being lost? Not knowing you are lost.” ...
  6. Can Paying Off Your Mortgage Early Hurt Your Net Worth?

    Saving your money and making double or even triple payments on a mortgage may sound productive, ...
Trading Center